celecoxib has been researched along with Cardiac Failure in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0." | 7.85 | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. ( Ahmad, S; Dubey, K; Fahim, M; Kohli, K; Panda, BP, 2017) |
| "To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib." | 7.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 5.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0." | 3.85 | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. ( Ahmad, S; Dubey, K; Fahim, M; Kohli, K; Panda, BP, 2017) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "Nonsteroidal antiinflammatory drugs (NSAIDs) as a class have been shown to increase the risk of congestive heart failure (CHF) compared with celecoxib." | 3.74 | Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? ( Hudson, M; Pilote, L; Rahme, E; Richard, H, 2007) |
| "To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib." | 3.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "These findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to non-NSAID controls." | 3.72 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. ( Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, M; Naglie, G; Rochon, PA; Stukel, TA, 2004) |
| "To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice." | 3.71 | Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. ( Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ, 2002) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 1.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| " Inhibition of COX-2 has been associated with the therapeutic effects of NSAIDs, whereas inhibition of COX-1 is believed to be the cause of the adverse gastrointestinal effects associated with NSAID therapy." | 1.31 | A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. ( Arellano, FM; Lejkowith, J; Reynolds, MW; Whelton, A; Zhao, SZ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ungprasert, P | 1 |
| Srivali, N | 1 |
| Kittanamongkolchai, W | 1 |
| Ahmad, S | 1 |
| Panda, BP | 1 |
| Kohli, K | 1 |
| Fahim, M | 1 |
| Dubey, K | 1 |
| Raynauld, JP | 1 |
| Martel-Pelletier, J | 1 |
| Beaulieu, A | 1 |
| Bessette, L | 1 |
| Morin, F | 1 |
| Choquette, D | 1 |
| Haraoui, B | 1 |
| Abram, F | 1 |
| Pelletier, JP | 1 |
| von Haehling, S | 1 |
| Stepney, R | 1 |
| Anker, SD | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Cocco, G | 1 |
| Whelton, A | 3 |
| White, WB | 1 |
| Bello, AE | 1 |
| Puma, JA | 1 |
| Fort, JG | 1 |
| Zhao, SZ | 2 |
| Burke, TA | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Cheng, TO | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| Mamdani, M | 1 |
| Juurlink, DN | 1 |
| Lee, DS | 1 |
| Rochon, PA | 1 |
| Kopp, A | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Stukel, TA | 1 |
| Hudson, M | 2 |
| Richard, H | 2 |
| Pilote, L | 2 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Rahme, E | 1 |
| Jacobshagen, C | 1 |
| Grüber, M | 1 |
| Teucher, N | 1 |
| Schmidt, AG | 1 |
| Unsöld, BW | 1 |
| Toischer, K | 1 |
| Nguyen, VP | 1 |
| Maier, LS | 1 |
| Kögler, H | 1 |
| Hasenfuss, G | 1 |
| McGettigan, P | 1 |
| Han, P | 1 |
| Jones, L | 1 |
| Whitaker, D | 1 |
| Henry, D | 1 |
| Reynolds, MW | 1 |
| Lejkowith, J | 1 |
| Arellano, FM | 1 |
3 reviews available for celecoxib and Cardiac Failure
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progression; Heart Failure; Humans; Lact | 2015 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
1 trial available for celecoxib and Cardiac Failure
| Article | Year |
|---|---|
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
15 other studies available for celecoxib and Cardiac Failure
| Article | Year |
|---|---|
Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model.
Topics: Animals; Cardiotoxicity; Celecoxib; Disease Models, Animal; Folic Acid; Heart Failure; Male; Random | 2017 |
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cohort Studies; Cycl | 2010 |
Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
Topics: Anabolic Agents; Animals; Appetite Stimulants; Cachexia; Celecoxib; Congresses as Topic; Drug Therap | 2010 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors | 2012 |
Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2002 |
No success with the SUCCESS trial.
Topics: Abbreviations as Topic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; | 2003 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; | 2004 |
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Celecoxib; Cohort Studies; Cyclooxyge | 2005 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2007 |
Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction.
Topics: Animals; Blood Pressure; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Celecoxib; Cyclooxyg | 2008 |
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2008 |
A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Topics: Acute Kidney Injury; Angiotensin Amide; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxy | 2001 |